In Brief This Week: Physician's Choice Laboratory Services, Predictive Biosciences; Microsaic Systems; Protea Biosciences | GenomeWeb

NEW YORK (GenomeWeb News) – Toxicology and genetics lab Physician's Choice Laboratory Services has acquired the CertNDx Bladder Cancer diagnostic testing assets from Predictive Biosciences for an undisclosed amount. The CertNDx Bladder Cancer Assay is a urine-based test that uses protein biomarkers and molecular DNA analysis to detect the presence or absence of urothelial cancer in patients presenting with hematuria. It stratifies patients based on their likelihood of bladder cancer and disease progression.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.